patritumab
seminoma
teprotumumab
malignin
teratocarcinoma
taplitumomab
tabalumab
ertumaxomab
catumaxomab
mapatumumab
amivantamab
alacizumab
oportuzumab monatox
-mel-
tumorous
tisotumab
caplacizumab
sibrotuzumab
testiculomata
pseudocapsule
dalotuzumab
oncotropic
-gov-
edrecolomab
iratumumab
citatuzumab bogatox
oncoimmunology
pintumomab
neoplastic cell
-mab
zalutumumab
monoantibody
agonistic monoclonal antibody
cergutuzumab
immunoenzymatic
immunochemiluminometric
antimonoclonal
durvalumab
apolizumab
pritumumab
-mar-
histiocytoma
microlymphocytotoxicity
ensituximab
malignancy
onco-
nimotuzumab
oncocytoma
nacolomab tafenatox
colosphere